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A.  In t roduct ion  
There have been many recent advances in 
understanding the pathophysiology and evolution 
of osteoarthrit is (OA). These advances have led to 
improvement in diagnosis and therapy, and have 
prompted a re-evaluation of the methodology and 
metrology involved in the performance of clinical 
trials in OA. Recently, a combined committee of 
the World Health Organization (WHO) and 
International League of Associations for Rheuma- 
tologists (ILAR) has defined two classes of 
symptomatic therapy based on the onset and 
duration of the response to treatment [1], and has 
proposed a third classification for agents that may 
alter the disease process. In addition, a workshop 
sponsored by the WHO and the American Academy 
of Orthopedic Surgeons (AAOS) has reviewed 
methods to assess progression of OA of the hip and 
knee [2]. At the request of the U. S. Food and Drug 
Administration, an independent committee has 
developed a Set of guiding principles for the 
development of new drugs for OA [3]. Sub- 
sequently, the European Group for the Respect of 
Ethics and Excellence in Science (GREES), 
through a subcommittee, has made recommen- 
dations regarding the methods to be used for 
registration of drugs for OA [4]. Most recently, the 
Outcome Measures in Arthritis Clinical Trials 
(OMERACT) group has recommended a core set of 
measures to be used in OA clinical trials [5]. 
The Osteoarthritis Research Society also estab- 
lished a Task Force to address the issue of clinical 
trial guidelines for OA. Through a series of 
meetings, a draft manuscript was developed. The 
intent of the Task Force was to bring together the 
ideas on the conduct of clinical trials generated by 
the relevant active working groups, and to add 
sufficient detail to be of help to any party involved 
in the design of clinical trials. The Task Force was 
composed of academic and clinical physicians, 
researchers in the pharmaceutical industry and 
members of GREES. Representatives of regulatory 
agencies were invited to attend all meetings. 
On May 26 and 27, 1996, a Workshop attended by 
representatives of the basic and clinical sciences, 
the pharmaceutical industry, GREES, and regulat- 
ory agencies was held in Washington, D. C. to 
discuss the working document of the Task Force. 
The present document resulted from the Workshop 
and reflects a consensus of the participants (See 
Appendix I). 
It can be expected that the metrology and 
methodology of clinical trials of drugs for OA will 
change in the future, as they have in the past [6, 7]. 
The following recommendations for the design of 
clinical trials in patients with OA are made with 
the understanding that they will require modifi- 
cation as new information becomes available. 
Investigators, regulatory and sponsoring agencies 
should be aware of the likelihood of such changes. 
Investigators and sponsors will need to incorpor- 
ate new methodologies into their protocol design, 
and regulatory agencies will require flexibility to 
adapt to the newer technologies and method- 
ologies. Indeed, as part of the advancement of 
science, it i s  expected that OA protocols will 
contain both validated measures and investiga- 
tional outcome measures till requiring validation. 
The following are recommendations, or guidelines, 
not rigid rules for the conduct of clinical trials in 
OA. Many of the recommendations are supported 
by published clinical research. However, some 
recommendations have yet to be validated and are 
based on the best judgment of the Task Force and 
the participants of the Workshop. 
B. Ob jec t ives  fo r  t reatment  o f  OA 
Medications for OA may affect symptoms and/or 
modify structure (joint pathology). Demonstration 
of these benefits will depend upon the trial design 
and outcome parameters selected. Trial design will 
depend on the mechanism of action of the drug and 
the expected response. 
For trials related to symptoms, some measure of 
joint pain will usually be the primary outcome 
variable. Factors that are considered in trial 
design include, but are not limited to, the 
pharmacodynamics of the drug, time to clinical 
response, duration of benefit after discontinuation 
of treatment, route of administration, frequency 
and severity of adverse events, effects on pain, 
effects on inflammation and effects on other 
symptoms and signs of the disease. In contrast o 
a prior consensus publication [1], the majority of 
the members of the Task Force and participants in 
the Workshop felt that there is no advantage in 
creating a separate class for those agents that 
produce a rapid symptom response from those with 
a slower onset of benefit. Medications used to treat 
syml~toms have generally included analgesics and 
nonsteroidal anti-inflammatory drugs (NSAIDs). 
Examples of agents that may prove to be of benefit 
with a particularly prolonged onset to pain relief 
include intra-articular (IA) hyaluronic acid, oral 
glucosamine, chondroitin sulfate and diacerrhein. 
For the purpose of this report, the term symptom 
modifying drugs for OA will be used for both rapid 
and slow onset agents. 
A drug may have effects on joint structure/func- 
tion independent of its effects on symptoms. 
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Studies of drugs that are expected to modify the 
pathologic process of OA should measure outcome 
parameters that reflect an alteration of joint 
structure. Such drugs may (1) prevent the 
development of OA, and/or (2) prevent, retard, 
reverse, or stabilize the progression of established 
OA by altering the underlying pathologic pro- 
cess(es). A drug that affects the pathology of OA 
may have no direct effect on joint symptoms. 
Symptomatic improvement may occur only after a 
prolonged period of administration. Demon- 
stration of symptomatic improvement is not 
required if no claim is made for this outcome. 
Indeed, the GREES group have clearly separated 
those drugs that may alter the structure without 
an affect on symptoms from those that, modify 
structure and do effect symptoms [4]. Whether 
related to symptoms, function or some other 
variable, the primary outcome measure should be 
clinically relevant. 
Drugs with a potential for structure modification 
have been labeled as 'chondroprotective', disease 
modifying drugs for OA (DMOADs), 'anatomy 
modifying agents', 'modifiers of morphology', etc. 
There is no uniformity of opinion concerning the 
term that best reflects the action of these agents. 
For the purposes of this report, and to provide 
consistency in the l iterature [4], the term structure 
modifying drugs will be used. To date, no agent has 
been proved to have structure modifying proper- 
ties in humans. It should be pointed out that a 
symptom modifying drug may prove to have 
structure modifying properties (favorable or dele- 
terious), just as a structure modifying drug may 
have symptom modifying properties. 
C. Leve ls  o f  c l in ica l  t r ia ls  for  OA 
Preclinical studies are helpful in assessing 
potential modes of action and the dose range for 
benefit/toxicity, and may shorten the duration of 
clinical testing of a potential structure modifying 
drug. Although they are not essential, studies that 
demonstrate efficacy in animal models of OA will 
strengthen the rationale for clinical trials of 
structure modifying drugs in humans. 
Medications undergoing clinical investigation 
are allocated to different levels of development as 
described below [8]. 
C.1. PHASE 1 TRIALS 
Phase 1 trials are directed principally at 
demonstrating pharmacokinetics and safety. They 
may also contain a dose-finding component. 
Escalating dose trials are desirable for initial 
evaluation of drug safety. Mechanism based 
pharmacological evaluations, including those at 
the site of action (i.e., in joint tissues), are 
common. Initially, the presence of comorbid 
conditions hould be minimized: later studies may 
target special populations, such as individuals 
taking concomitant medication. Phase 1 trials may 
be performed in normal volunteers or in a patient 
population appropriate for the target indication. 
Double-blind, placebo-controlled, single and mul- 
tiple dose Phase 1 trials are desirable for the initial 
evaluation of drug safety. Evaluation of efficacy is 
not the primary purpose of Phase 1 trials. A Phase 
1 trial cannot adequately address the benefits of 
structure modifying drugs. 
C.2. PHASE 2 TRIALS 
The goals of Phase 2 trials are to define an ideal 
effective dose range and regimen (Phase 2 trials 
must take into account both drug activity and 
toxicity) and to provide sufficient patient exposure 
to demonstrate safety in order to justify pro- 
gression to Phase 3 trials (See Below). The 
duration of the study and number of patients 
studied should be based on. the mechanism of 
action of the drug, duration of~action of the drug, 
outcome variable being assessed, variabil ity of the 
outcome parameters, and the intended patient 
population. Dose ranging in these and subsequent 
studies should identify the minimal effective dose 
and dose-response profile, and may define the 
maximum tolerated dose of the drug in patients 
with OA. 
C.2.1. Symptom odifying drugs 
Phase 2 studies of symptom modifying drugs for 
OA should be placebo controlled, randomized and 
double-blind. Efficacy can often be demonstrated 
within days. Longer studies (weeks) are needed to 
demonstrate slow onset or persistent benefit. Even 
longer studies are required for safety. In studies of 
long-duration, rescue analgesia may be necessary. 
A short-acting analgesic is suggested with a 
suitable washout employed prior to  efficacy 
assessment. 
C.2.2. Structure modifying drugs 
As an alternative to demonstrating effects on 
joint structure, dose-ranging studies in Phase 2 
trials of a structure modifying drug may utilize 
Other measures of mechanism-based drug activity. 
Because these are measures of physiology and not 
efficacy endpoints, multiple dose regimens may be 
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needed in late Phase 2 (2b) or Phase 3 trials. The 
duration of Phase 2 studies for a structure modi- 
fying drug wilt also depend on its mode of action. 
C.3. PHASE 3 TRIALS 
Phase 3 trials are intended to convincingly 
demonstrate efficacy and safety of the optimal 
regimen and dose(s) of the test agent. Replication 
of pivotal studies (studies of primary importance 
for registration of drugs) for demonstration f 
efficacy isrecommended. There should be only one 
target joint in a single trial These studies are 
designed to clearly define the dose/regimen of the 
test drug to be recommended for clinical use, 
further define toxicity, and compare the test drug 
with a reference drug and/or placebo. Sample size 
and study duration should be calculated to assure 
that subjects will be followed for a sufficient time 
period to detect aclinically relevant, as well as a 
statistically significant, difference between treat- 
ment and control groups with respect to efficacy-- 
outcome parameters ( ee Statistical Methods). 
Sufficient data must be supplied to the appropriate 
regulatory agency(ies) to satisfy safety concerns. 
The number of patients and length of time to assess 
safety should follow the recommendation f r
chronic diseases ofthe Guidelines for Industry [9]. 
C.3.1. Symptom odifying drugs 
Phase 3 trials of drugs with a rapid onset of 
effect can be as short as 4 weeks. At times, shorter 
trials are appropriate. Longer trials may be needed 
to evaluate fficacy for drugs with a slower onset 
of action. In studies of long-duration, rescue 
analgesia may be necessary. A short-acting 
analgesic is suggested with a suitable washout 
prior to assessment of efficacy. A Phase 3 double 
blind study may be followed by a long-term 
double-blind study or open-label extension to 
evaluate safety. 
C.3.2. Structure modifying drugs 
There are no proven structure modifying drugs. 
Hence, the extent of testing needed to demonstrate 
this effect is not established. The duration of the 
trial should be predetermined, and it is rec- 
ommended that it be at least 1 year. The duration 
will depend on the mode of action of the drug, the 
anticipated response rate, the primary outcome 
variable and the length of time needed to show a 
difference in comparison with a control (i.e., 
placebo) group. Structural changes are required as 
primary endpoints. The size of the study popu- 
lation be should be ideally cMculated on the basis 
of preliminary data from Phase 2 trials in the 
particular population to be studied (see Statistical 
Section). 
C.4. PHASE 4 TRIALS 
Phase 4 studies are performed after the agent has 
been approved for clinical use by the regulatory 
agency. These studies may be used to support 
clinical observations leading to expanded indi- 
cations. They also permit exploration of uncom- 
mon adverse vents that can be discovered only in 
studies with a large sample size. It also provides 
sUpportive evidence of long-term benefit. Some 
Phase 4 trials may be open label. To date; Phase 4 
trials have been published only for symptom 
modifying drugs. 
C.5.  REGULATORY ISSUES 
When evaluating OA medications, it is advisable 
(when applicable) for the sponsor to schedule a 
pre-investigational new-drug meeting with the 
appropriate regulatory agency to define the 
preclinical and clinical requirements prior to 
initiation of Phase 1 trials. The sponsor should 
maintain communication with the regulatory 
agency as the drug progresses through Phase 2 and 
Phase 3 studies. 
D. Enter ing  pat ients  in OA t r ia l s  
This section addresses everal aspects of the 
study design, including the protocol, admission 
criteria, selection of the study population and the 
definition of what is to be studied. Baseline 
assessment should provide information on joint 
localization (site), etiology (primary, secondary), 
severity of symptoms, structural abnormality in 
the joint, concomitant therapy and comorbidity [4]. 
D.1. OVERVIEW OF THE PROTOCOL 
.The study protocol should be divided into 
sections that encompass background information, 
rationale for the study, the question(s) being 
asked, size and site(s) of the study, method of 
patient selection (including inclusion and exclu- 
sion criteria), the method of procedure, clearly 
defined primary and secondary outcome variables, 
specific measures to be performed at each visit, 
drug dispensing format, method of reporting 
adverse vents, statistical analysis and regulatory 
issues (including drug accountability, institutional 
requirements, etc.). 
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It is desirable to include a table (or flow sheet) 
that outlines the method of procedure, information 
from selected references (e.g., disease classifi- 
cation, radiographic riteria), the informed con- 
sent statement, protocol worksheets, drug 
accountability forms, the data collection forms, 
etc. 
The protocol should carefully define the investi- 
gators, their study sites, the method of randomiz- 
ation, patient monitoring procedures, technical 
aspects of imaging techniques, laboratory tests, 
methods of documenting adverse vents, methods 
of blinding and method of documenting medication 
intake for each patient (active drug, placebo, 
rescue analgesia), and the method of maintaining 
the medication log for each participating center. 
D.2. DEMOGRAPHICS 
Demographics recorded in the protocol should 
include identifying information, such as the 
patient's name, address and telephone number, 
which should be kept confidential. The patient's 
name should be coded by letters/numbers for data 
processing and future reference. 
As a minimum, sociodemographic and clinical 
data collected at the time of enrollment into the 
study should include age (date of birth), sex, race, 
height, weight, marital status and years of formal 
education. 
D.3. DIAGNOSIS 
Criteria for diagnosis of OA should be clearly 
stated. Patients hould fulfill validated criteria for 
the classification of OA, such as those published by 
the American College of Rheumatology (ACR) 
[10-12]. The disease should be classified as primary 
or secondary. Study populations should be as 
homogenous as possible with regard to the 
presence of idiopathic (primary) or secondary OA 
[10]. If patients with secondary OA are studied, the 
underlying condition should be specified and 
should be the same in all patients (e.g., post-trau- 
matic arthritis, mechanical derangement of the 
knee). It is suggested that in studies of patients 
with idiopathic OA, exclusions for secondary OA 
of the study joint include septic arthritis, 
inflammatory joint disease, gout, Paget's disease of 
bone, recurrent pseudogout, articular fracture, 
major dysplasias or congenital abnormality, 
ochronosis, acromegaly, hemachromatosis, 
Wilson's disease and primary osteochondromatosis 
[4]. 
D.4. RADIOGRAPHS 
Theradiographic severity of OA in each patient 
should be quantified and documented using either 
aggregate radiographic riteria (e.g., Kellgren and 
Lawrence scale [13, 14]) or grading of specific 
radiographic features [15-17]. This estimate of 
anatomic alteration on images should be acquired 
within 3 months after entry. The range of grades 
used for entry criteria, as well as variations in 
grade among treatment and placebo (or control) 
groups should be comparable and similar. These 
radiographic entry criteria should also be appro- 
priate for the specific study design. For example, a
cohort that included advanced severity might be 
appropriate in studies of a symptom modifying 
drug while a cohort limited to minimal severity 
would be more appropriate for studies of a 
structure modifying drug intended to retard 
progression. 
D.5. STUDY POPULAT ION 
The source of the patient population (e.g., 
clinic-based, community-based, hospital-based) 
should be defined in the protocol. Considerable 
controversy exists regarding the use of broad vs 
narrow patient eligibility criterion. Broad patient 
eligibility allows for generalizable application of 
positive results; however, because of the larger 
amount of variation, broad patient eligibility 
increases the sample size of the study population 
required to demonstrate clinical and statistically 
significant differences, and may mask the presence 
of subsets receiving benefit (unless extensive 
stratification is performed). At the Workshop, the 
consensus was that patient eligibility should define 
specific populations and that, where appropriate, 
stratification of subgroups hould be employed 
within studies for secondary endpoints of interest. 
Examples of high-risk groups that might be 
considered for inclusion in studies of structure 
modifying drugs include obese women with 
unilateral radiographic knee OA [18], and men or 
women who have undergone meniscectomy [19, 20]. 
Examples of variables to be considered for 
stratification of the source population might 
include prior surgical intervention of the index 
joint, and high- vs low-risk groups. Examples of 
subjects who might be considered for exclusion 
might encompass either low- or high-risk popu- 
lations, such as young age (<45 years old) and 
those with protrusio acetabuli, concentric femoral 
head migration, extensive surgery of the reference 
joint, excessive varus/valgus deformity, concomi- 
tant rheumatic illness (e.g. fibromyalgia), and those 
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involved with l it igation/compensation related to 
the reference joint. 
D.5.1. Symptom odifying drugs 
For studies of symptomatic response, the level of 
symptoms at baseline should be of sufficient 
severity to permit detection of change, i.e., not too 
mild. After washout (see Section E.5.), inclusion 
criteria for symptomatic response should include 
the following: 
• Pain of at least mild intensity: e.g., 100 mm 
visual analog scale (VAS) recording of 
_>25 mm; or five point categorical (Likert) 
scale grade >- 1 (where 0 is no pain and 4 is 
extreme pain); 
• Definite radiographic hanges of OA, using an 
established scale and atlas, e. g., Kellgren 
and Lawrence radiographic grade >_2 for 
tibiofemoral OA (i.e., presence of a definite 
osteophyte); modified Croft scale _>2 for hip 
OA [13, 14, 21, 22]. 
D.5.2. Structure modifying drugs 
For studies of structure modifying drugs, as 
discussed above, special subpopulations of sub- 
jects who are at high risk for development of OA 
or rapidly progressive OA may be advantageous (as 
above). In addition, the following should be 
considered: 
• Kellgren and Lawrence radiographic entry 
criteria: prevention studies: grades 0 or 1 (i.e., 
absence of a definite osteophyte); disease 
retardation/reversal tudies: grades 2 or 3 (i.e., 
sufficient remaining interbone distance to 
permit detection Of worsening/progression); 
• Current or previous pain in the index joint 
is not essential. However, changes in pain 
may be examined as a secondary outcome 
measure 
Preliminary data Suggest that some molecular 
markers in serum may predict radiographic 
progression of established OA [23, 24]. Analysis of 
molecular markers may select subpopulations who 
are most likely to show progression in OA. 
D.6. INCLUSIONS/EXCLUSIONS 
Inclusion criteria should be clearly defined and 
should specify the population to be studied by age, 
sex, diagnostic criteria, joint with OA, degree of 
symptoms, and radiographic grade. 
Exclusion criteria should similarly be clearly 
defined with regard to degree of symptoms, 
radiographic grade, concomitant disease, prior 
peptic ulcer disease (if a drug is perceived to have 
gastrointestinal effects), concomitant medications, 
pregnancy/contraception, IA depocorticosteroid or 
hyaluronic acid injection, tidal lavage, secondary 
OA (listed above). 
Opinion varies concerning the proximity to the 
beginning of a study for administering IA 
medication into the reference joint. All agreed that 
there should be a sufficient interval between the 
time of the injection and the beginning of the study 
to eliminate the confounding effects of the 
injection on joint pain. The consensus of the 
participants at the Workshop was that a minimum 
of 3 months should elapse between the time of the 
IA injection and the trial (e.g., IA corticosteroids). 
This interval may be longer for specific types of IA 
therapy (e.g., IA hyaluronan), but sufficient 
evidence is not available to provide more definitive 
guidance at this time. The investigator should 
consider stratification of patients receiving prior 
IA theral]y administered within a year of the 
study. 
Additional exclusions are significant injury to 
the affected joint within 6 months of trial start; 
arthroscopy of the affected joint within 1 year; 
disease of spine or other lower extremity joints of 
sufficient degree to affect assessment of the target 
joint, use of assistive devices other than a cane 
(walking stick) or knee brace, concomitant 
rheumatic disease (e.g., fibromyalgia), or poor 
general health interfering with compliance or 
assessment. 
As with any investigational drug, women of 
childbearing potential should be screened for 
pregnancy, and if pregnant, should be excluded 
from the trial. 
D.7. OA HISTORY 
The OA history is used to characterize the study 
population and should include the location and 
number of symptomatic OA joints; presence of 
hand OA (e.g., Heberden's nodes in patients with 
hip or knee OA); duration of symptoms; duration of 
the diagnosis of OA; history of prior medications 
for OA; surgical procedures performed on the study 
joint (including arthroscopy), with the date of the 
most recent procedure; use of assistive devices, 
such as canes, crutches, knee braces (in studies of 
lower extremity OA); history of prior IA (e.g. 
depocorticosteroid or hyaluronan) injection, with 
date of most recent injection (see above). 
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D.8. HISTORY (OTHER) 
Other baseline history that may be of value 
includes smoking history, hormonal status in 
postmenopausal women, concomitant chronic dis- 
ease, and concomitant medications, e.g., estrogens, 
anti-inflammatory drugs. 
D.9. STUDY JOINT 
Protocols should be limited to the evaluation of 
a single joint site (e.g., knee, hip) or in the case of 
hand OA, either both hands or the symptomatic 
hand (preferably the dominant hand). 
D.9.1. Symptom odifying drugs 
Although data may be collected for both right 
and left joints (e.g. knee, hip), for symptom studies 
only one should be the primary joint evaluated 
(except for hands as above). This is most often the 
signal (more symptomatic) side. Changes in the 
contralateral joint should be considered as a 
secondary outcome variable. 
D.9.2. Structure modifying drugs 
For studies of a structure modifying drug, the 
more involved side of a single joint site (e.g., hip, 
knee) should be studied as the primary outcome 
variable. In these cases, changes in the contralat- 
eral joint can serve as a secondary outcome 
variable. However, changes in the contralateral 
joint, which may not yet be symptomatic or have 
definite OA, may be selected as the primary 
outcome variable (e.g. Chingford data) [18]. 
For studies of both symptom and structure 
modifying drugs, additional joint sites may be 
evaluated as secondary outcome variables. 
D.10. PHYSICAL EXAMINAT ION OF THE INDEX JO INT  
Baseline information about the index joint helps 
characterize the study population and provides 
reference data for assessing how variables of 
interest have changed during the course of 
treatment. Evidence of inflammation (e.g., joint 
effusion), joint deformity, and joint contractures 
should be noted. For large joints, loss of range of 
motion and presence of severe valgus/varus 
deformity may be useful as exclusion criteria. 
Although it is important o record the presence of 
clinical signs of inflammation, including synovial 
effusion, these should not be used as a primary 
outcome measure in trials of structure modifying 
drugs. 
D.11. FUNCTION 
Measuring the degree of functional impairment 
can identify the severity of disease in the study 
population. Functional impairment should be 
defined using a segregated, validated multidimen- 
sional index (SMI) such as the Western Ontario 
and McMasters Universities (WOMAC) [25] OA 
index for hip and knee OA, or an aggregated 
multidimensional index (AMI) such as the Algo- 
functional Index (AFI) for hip or knee [26]. At this 
time, a l though the AFI has been validated, 
separate pain, stiffness and physical function 
subsections have not been validated for indepen- 
dent application. 
D.12. GENERAL PHYSICAL  EXAMINAT ION 
A general physica] examinat ion  should  be 
per formed at the onset of the study and  again at 
the end  of the study. 
D.13. INFORMED CONSENT 
Guidelines for information to be contained in the 
Informed Consent statement should be in accord- 
ance with the Declaration of Hetsinki [27]. Patient 
participation requires understanding, and com- 
pletion of an informed consent document hat has 
been approved by the appropriate institutional 
review board. 
E. Conduct  o f  the  s tudy  
This section deals with the procedures used 
during the study, exclusive of individual outcome 
variables. 
E.1 .  STUDY DESIGN 
Studies should generally be single joint, con- 
trolled, randomized, double-blind, and parallel in 
design. Occasionally, crossover studies or other 
designs may be appropriate. 
The study should include a screening and 
baseline visit. The two visits allow the collection 
of more reliable baseline data, assure that the 
patients fulfill entry criteria and may be used to 
help reduce noncompliance ('faintness-of-heart 
test' [28]), collect biological specimens, etc. For 
treatment group assignment, patients should be 
randomized in the order in which they are enrolled 
into the study, to receive treatment according to a 
randomization schedule specifically designed to 
meet study objectives. 
At each visit, vital signs (blood pressure, pulse, 
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and weight) should be recorded and a report of 
adverse experiences (see below) obtained. 
In order to minimize unwanted sources of 
variation in patient assessment, to the extent 
possible, the same examiner should examine the 
same patient at each visit, at the same time of day 
(and preferably also on the same day of the week) 
throughout he duration of the trial. 
E.2.  PRIMARY STUDY OUTCOME 
Efficacy studies of OA drugs should preferably 
identify a single clearly defined primary outcome 
variable. The choice of this variable will depend 
upon the nature of the desired drug effect and the 
objective of the study. 
An alternative approach might involve the use 
of several primary outcome variables. With this 
latter approach, adjustments to the significance 
level are required for multiple analyses performed. 
(See Outcome Measures below.) 
E.3. SECONDARY STUDY OUTCOMES 
The inclusion of one or more secondary outcome 
variables will strengthen the study design. Collec- 
tion of information for the secondary outcome 
variables should not interfere with collection of 
data for the primary outcome variable. 
E.4. EXAMINER 
The method used for training and masking of the 
examiner and masking of the patient must be 
specified. Both a blinded investigator (to assess the 
patient for efficacy and adverse events) and an 
unblinded investigator may be needed to adminis- 
ter the test medication and monitor toxicity in 
some studies. 
E.5. • WASHOUT REQUIREMENTS 
E.5.1. Symptom odifying drugs 
All symptom-oriented studies require discontinu- 
ation of prior analgesic and anti-inflammatory 
medications, including topical agents, prior to 
initiating treatment with the test drug in order to 
permit an evaluation of unmodified pain severity. 
The time of withdrawal should be the time required 
for the clinical effect to disappear (e.g., 5 half-lives 
of the drug). During the washout period, subjects 
may use acetaminophen (or paracetamol) as rescue 
analgesia (up to 4 g/day in the U.S. and up to 
3 g/day in Europe). This must be discontinued in 
sufficient ime for the clinical effects of the rescue 
drug to disappear. 
Worsening of symptoms during the washout 
per iod--a l though not necessarily a requisite for 
subject inclusion into the tr ia l - -should be docu- 
mented. 
E.5.2. Structure modifying drugs 
A washout period is not required in trials of a 
structure modifying drug. If however, the effect of 
the drug on symptoms is to be tested, then the use 
of a washout period should be considered. 
E.6. ADMINISTRATION OF STUDY MEDICATION 
Control agents may include placebo or active 
(e.g., analgesic or NSAID) agents. Use of placebo 
may be influenced by ethical and regulatory 
agency considerations. Active control agents offer 
the advantage of demonstrating improved efficacy 
over existing therapies, but may require large 
numbers of subjects. 
E.6.1. Topical 
Topical test medications hould be dispensed in 
containers which are identical in appearance to 
those containing the comparison agent (drug or 
placebo). The comparison agent should mimic the 
test medication in appearance, odor and local 
effects on the skin. Clear instructions regarding 
use must be provided to the patient both orally and 
in written form and must be contained in the 
Informed Consent. Compliance should be moni- 
tored by weighing the returned tubes or measuring 
the returned liquid. Placebo responses are particu- 
larly frequent with this technique of drug delivery, 
so placebo controlled trials are particularly 
important, as are carefully defined, homogeneous 
study populations. 
E.6.2. Oral 
Oral test medications hould be formulated to 
provide an appearance identical to that of the 
comparison drug (placebo or other). If this is not 
feasible, a 'double dummy' technique (two non- 
identical active agents, each with an identical 
matching placebo) should be used. 
Preferably, medication should be dispensed in 
blister packs with the label clearly stating the day 
and time of administration. Compliance should be 
monitored by counting returned unused medi- 
cations or by use of medication vials with 
computerized caps. 
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Concomitant medication (e.g., rescue analgesia 
and NSAIDs in studies of structure modifying 
drugs) may be dispensed in bottles. The pills should 
be counted at each visit. Analgesic drugs with a 
short half-life should not be taken from the evening 
prior to the day of the evaluation if pain is to be 
evaluated. 
E.6.3. Parenteral medication 
Parenteral medication should be formulated to 
provide an appearance identical to that of the 
comparison drug. If this is not possible, the 
parenteral medication should be dispensed by a 
person other than the blinded investigator (e.g., by 
an unblinded investigator) and the injectable 
agent should be concealed from both the patient 
and the blinded evaluator. 
E.6.4. IA Medication 
IA study medication should be formulated to 
provide an appearance identical to that of the 
comparison drug. If this is not possible, the 
medication should be injected by a physician other 
than the blinded investigator (e.g., unblinded 
investigator). The volume of control (carrier) 
injected should equal the volume of the test agent. 
The joint should be aspirated to remove any 
existing effusion as completely as possible prior to 
instil lation of the drug, and the volume of fluid 
removed should be recorded. The injectable should 
be concealed from both the patient and the blinded 
evaluator. Placebo responses are particularly 
frequent with this technique of drug delivery, so 
placebo controlled trials are particularly import- 
ant, as is the use of carefully defined homogeneous 
study populations. 
E.7. COMPLIANCE AND SUBJECT RETENTION 
It is essential for studies of structure modifying 
drugs, that strategies be employed to maximize and 
document patient compliance. For example, con- 
tact might be maintained with patients at 4-8 week 
intervals by telephone. The method of communi- 
cation and time spent with patients should be 
standardized as much as possible without jeopar- 
dizing the relationship with the patient. 
E.8. SOCIOECONOMIC MEASURES 
Sponsors should consider performing pharma- 
coeconomic analyses in all OA clinical trials 
[29, 30]. 
E.9. USE OF CONCOMITANT MEDICATIONS 
E.9.1. Symptom modifying drugs 
It is impractical to expect patients to participate 
in a long-term trial without some potential for use 
of rescue medications for pain. For long-term 
trials, use of concomitant medication should be 
permitted on a limited basis. An example may be 
the use of acetaminophen (or paracetamol) for 
escape analgesia (up to 4 gm/day in the U.S. and up 
to 3 gm/day in Europe). Any escape medication 
must be discontinued in sufficient time for the 
clinical effects of the agent to disappear prior to 
the assessment. Protocol design should include a 
record of the consumption of analgesics, NSAIDs, 
and IA injections. However, the use of such 
information as an outcome in clinical trials has not 
been validated. 
IA depocorticosteroids should not be permitted 
in studies of symptom modifying drugs, except as 
part of the protocol design. 
E.9.2. Structure modifying drugs 
Concomitant herapy may interfere with the 
evaluation of outcome measures and should ideally 
be excluded. However, in long~term studies, it is 
neither ethical nor practical to exclude all 
concomitant treatments. In all trials, concomitant 
therapies (drugs or other interventions) that are 
likely to affect joint structure should be excluded, 
and rescue therapy should be standardized, 
carefully recorded and monitored. As noted above, 
participants may use acetaminophen (or paraceta- 
mol) for escape analgesia (up to 4 g/day in the U.S. 
and up to 3 g/day in Europe). Analgesics and 
NSAIDs must be discontinued prior to the 
assessment in sufficient time for the clinical effects 
of the rescue medication to disappear. 
The consumption of analgesics, NSAIDs, and IA 
injections should be documented at each visit. 
However, methods need to  be developed to 
effectively control for these confounding variables 
in the analysi s and the use of this information has 
not been validated as an outcome variable. 
E.10. CONCOMITANT NON-MEDICINAL THERAPY 
Concomitant reatment with physical and/or 
occupational therapy should be either standard- 
ized or adjusted for in the analysis to ensure that 
the effects of exercise programs on disease 
progression do not bias the outcome of the study. 
Information on weight change (reduction or gain), 
changes in use of ambulatory support (cane, 
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crutches, walker), and introduction of, or changes 
in, physical or occupational therapy during the 
study should be incorporated into the study design. 
E.11. LABORATORY TESTS 
For most multicenter studies, routine laboratory 
tests (complete blood count, urinalysis, serum 
chemistry determinations) should be performed in 
a central aboratory. 
Routine synovial fluid analyses should be 
performed at each site, and should include an 
examination for cells and crystals. 
For studies routinely performing arthrocentesis 
with injection of an IA agent, culture of the 
synovial fluid should be performed as clinically 
indicated. 
E.12. ADVERSE EVENTS 
Adverse events should be ascertained in an 
open-ended manner, rather than by checklist. They 
should be recorded at each visit and between visits, 
as appropriate. The date of onset, severity, a 
judgment with respect o the relationship between 
the adverse vent and the test agent, treatment and 
the duration, and resolution of the adverse vent 
should all be recorded. 
Serious adverse events should be reported to 
regulatory authorities immediately. 
E.13. PROTOCOL VIOLATION 
Reasons for termination of a subject from the 
study due to protocol violation must be specified in 
the protocol. Intake of rescue medications (other 
than those specifically prescribed), use of oral or 
topical agents, or devices targeted toward pain 
relief during the course of the study should be 
prohibited. Information on the use of such agents 
should be obtained at each visit and recorded, and 
the patient should be warned about such co-inter- 
ventions. Patients in repeated violation of the 
protocol may need to be dropped from the study. 
Screening for protocol violations by performing 
blood or urine analyses for salicylates or related 
agents is not considered useful. 
E.14. CASE REPORT FORMS AND SUPPL IES  
Investigators must maintain adequate records 
showing the receipt, dispensing, return, or other 
disposition of the investigational drug, including 
the date, quantity, batch or code number, and 
identification of subjects who received the study 
drug. Investigators must maintain completed case 
report forms and informative source documents. 
Case report forms must be kept in locked cabinets 
to maintain security. There are no special 
requirements for OA trials. 
F. Outcome measures  o f  OA 
Instruments used to measure outcome in clinical 
trials of OA should be valid, reliable and 
responsive to change, when such measures exist. 
Clinical trials in OA should use published 
instruments that have been used in other studies, 
thus permitting comparison of results across trials 
of different therapeutic interventions. Clinical 
trials in OA should include a core set of validated 
measures [5] (Appendix II): 
• Pain 
• Physical function 
• Patient global assessment 
• Imaging (for studies >_ 1 year in duration) 
Additional measures that are recommended in- 
clude the following: 
• Quality of life/utility (strongly recommended) 
• Physician global assessment 
Optional measures for trials in OA include the 
following: 
• Signs of inflammation 
• Biologic markers 
• Stiffness 
• Performance based measures of function 
• Presence of 'flares' 
• Time to surgery 
• Analgesic consumption 
The items listed below pertain mostly to phase 3 
trials. These measures should be recorded at 
baseline and serially at appropriate intervals. 
F.1. SYMPTOM MODIFYING DRUGS 
For studies of drugs designed to affect symptoms, 
the primary outcome variable should usually be 
joint pain reported by the patient. Measurement 
should be serially recorded at appropriate inter- 
vals, at least monthly. However, this is dependent 
upon the target joint and study design. 
F.1.1. Pain 
The degree of joint pain in the index joint(s) 
should be graded. Pain should be recorded on a 
five-point Likert scale (e.g., none, mild, moderate, 
severe, very severe) or on a 100 mm VAS. Single 
questions about pain can be used but the activity 
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causing pain should be specified: e.g., weight 
bearing, resting, nocturnal, post exercise, stair 
climbing. Alternatively, a validated pain instru- 
ment can be used (e.g., WOMAC pain subscale 
[24]). Other pain indices include the Health 
Assessment Questionaire (HAQ) [31] and Arthritis 
Impact Measurement Scale (AIMS) [32]. 
F.1.5. Joint examination 
Measures of range of motion, intermalleolear 
distance, knee interbone distance, heel to buttock 
measurements, knee circumference, tc. have been 
validated to variable degrees [42]. The usefulness 
of these measures in clinical trials remains unclear 
and their inclusion is optional. 
F.1.2. Function 
The AFI [25] and the function subscale of the 
WOMAC [24] have been validated and are 
recommended for studies of OA of the hip and 
knee. Other indices which have been used include 
the HAQ disability index [28], and AIMS [33]. 
Disability indices specifically designed to measure 
hand function are under development [34, 35]. 
F.1.6. Performance-based measures 
Performance-based measures which include such 
items as grip strength, time to walk a specified 
distance (e.g., 6 or 15 m, 50 ft), distance walked in 
a specified time (e.g., 6 min)., have been studied to 
a variable degree. Some composite measures exist 
[43]. The usefulness of these measures in clinical 
trials remains unclear and their inclusion is 
optional. 
F.1.3. Global status 
F.1.3.a. Patient assessment of global status. The 
patient's assessment of his/her global status hould 
be measured using a Likert or VAS scale. The 
optimal method by which this should be measured 
is not well established. However, a standard 
question should be asked, e.g., 'Considering all the 
ways your OA (joint site) affects you, how are you 
doing (time frame)?' 
F.1.3.b. Physician assessment of global status. A 
measure of the physician assessment of global 
status may be required by some regulatory 
agencies. There is no generally accepted method 
for measurement of this variable. A question such 
as 'Considering all information, how is the 
patient's OA [joint site] today?' should be used 
with a VAS or Likert scale. 
F.1.4. Quality of life scales 
Measurement of health-related quality of life 
and util ity based measures at appropriate intervals 
is strongly recommended; although, these are not 
a part of the core set of measures. Examples of 
health related quality of life instruments include 
the Medical Outcomes Study, 36 question short 
form (SF-36) [36], Sickness Impact Profile (SIP) 
[37], Nottingham Health Profile (NHP) [38], and 
EuroQol [39]. Examples of util ity instruments 
include the Time Trade Off, the Standard Gamble 
and Techniques and Feeling Thermometer and the 
Health Utilities Index (HUI) [40, 41]. 
F.1. 7. Inflammation 
Clinimetric properties of methods designed to 
measure inflammation have not been well eluci- 
dated. The usefulness of these measures in clinical 
trials remains uncertain. 
F.1.8. Response criteria 
There is no definition of a minimum clinically 
important response for the above measures. 
Available information does not allow setting of 
predetermined limits for improvement. This is 
particularly true for the composite indices. At this 
time, the Task Force recommends that each 
protocol predefine a significant response, based 
upon statistically significant improvement in a 
carefully defined primary efficacy variable (see the 
statistical section below). At this time, the Task 
Force does not recommend using an individual 
response criterion such as has been recommended 
in rheumatoid arthritis [44]. 
F.2. STRUCTURE MODIFY ING DRUGS 
For studies of potential structure modifying 
drugs, the primary outcome variable should be a 
measure of joint morphology; e.g., imaging (see 
below) or direct visualization, i.e., arthroscopy. As 
stated above, time to joint replacement surgery is 
not recommended as a primary outcome variable 
due to its dependence on factors unrelated to 
disease progression. Clinical follow-up of patients 
participating in trials of structure modifying drugs 
should be at intervals of 3 months or less. 
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F.2.1. Radiography 
The primary radiographic evaluation should be 
of a single joint (knee, hip, hand). Outcome should 
assess the effect of the drug on joint structure. 
Although assessment should include both carti lage 
and bone, the primary radiographic outcome 
variable for studies of progression of the hip and 
knee should be minimum joint space width (JSW), 
since this measure is more sensitive than global 
scoring [45-49]. Osteophytes and other bone 
changes should be assessed as secondary outcome 
variables either by measurement or by grading, 
using published atlases [13-17]. In contrast, for 
studies of prevention, the primary radiographic 
outcome variables should include osteophytes, 
since this feature is most strongly associated with 
knee pain, is a basic component of the ACR 
classification criteria, and is the hallmark of the 
Kel lgren-Lawrence scale of the knee. Outcome 
variables for hand OA should be based on 
published atlases agreed upon by the study group 
in advance. 
Obtaining reproducible X-rays on successive 
visits is a prerequisite for reliable assessment of 
progression of OA. The sources of variabil ity in 
joint space width measurement are numerous 
(patient positioning, radiographic procedure, 
measurement process, etc.), protocols have been 
proposed for hip and  knee joints [50-52]. It is 
essential to standardize radiographic technique 
based on published, validated data (Appendix III). 
The method should define the radio-anatomic 
position of the joint, beam alignment, and should 
define the anatomic landmarks for measurements. 
Positioning of the patient should also be based on 
val idated published methods, but in all cases, 
weight bearing (standing) anteroposterior views 
should be used in studies involving the hip or knee. 
Repositioning of the joint can be facilitated by use 
of foot maps drawn at the time of the initial 
examination. Correction for radiographic magnifi- 
cation has been shown to improve accuracy and 
precision of measurements [48, 53]. Techniques 
that improve the precision of measurements might 
lead to studies requiring smaller sample sizes. 
Quality assurance should include training 
sessions for technologists at the onset of the study 
as well as for any technologists recruited during 
the study. Radiographic quality, including patient 
positioning, exposure, labeling, etc., should be 
monitored throughout the study. Even minor 
changes in technique may significantly alter the 
precision of measures of joint anatomy and hence 
conclusions about treatment response. It is, 
therefore, critical that the technique be identical 
at all centers involved in a multi- institutional 
study and remain consistent throughout the study. 
The number of readers, method of blinding and 
the method of manual measurement should be 
agreed upon in advance by the study group. 
Quality control of the readings should include an 
initial training session and periodic assessments of
performance. Validated methods for computerized 
reading of digitized radiographs can decrease 
observer-based rror. Enhanced anatomical detail 
provided by microfocal magnification radiography 
can further improve precision and accuracy of 
measurements [48, 54]. 
F.2.2. Magnetic resonance imaging (MRI) 
MRI is uniquely capable of visualizing all 
components of the joint simultaneously, and 
therefore offers an opportunity to asses the joint as 
an organ. MRI is capable of quantifying a number 
of morphological and compositional parameters of 
articular tissues relevant to OA. Recently devel- 
oped techniques for noninvasively quantifying 
cartilage volume, thickness and water content, 
particularly in early disease, show promise as 
potential outcome measures for future therapeutic 
studies (Appendix IV). While some cross-sectional 
measures have been validated, their performance 
in longitudinal studies has yet to be determined. 
F.2.3. Other imaging modalities 
Computed tomography, ultrasonography and 
scintigraphy have not been adequately val idated 
and cannot be recommended for use in long-term 
studies. 
F.2.4. Arthroscopy 
Arthroscopy can directly visualize carti lage and 
other IA structures, including f ibrocarti lagenous 
menisci, synovium, ligaments and chondrophytes. 
Attempts to quantify this information have 
followed two strategies. The first transforms 
information from each cartilage lesion into a 
numeric score, weighted mainly by depth and size 
of the lesion. When several lesions are found, as 
occurs frequently in OA, a composite score is 
derived from the scores of individual lesions. The 
second approach calls for the arthroscopist o 
globally assess cartilage degeneration in a 
compartment-by-compartment fashion, recording 
each impression on a VAS. Both strategies are 
being employed in the two systems currently 
under evaluation, with intra- and inter-observer 
reliability determined for both [55,56], and 
230 OARS Clinical Trials 
sensitivity to change (utilizing videotaped records 
from two points in time) has been shown for the 
French system [51]. 
Other systems yet to be devised may prove 
superior for assessment of particular aspects of 
OA, examining biomechanical characteristics of 
cartilage (which might be shown better by a probe) 
or features of the accompanying synovitis. The 
precision and sensitivity to change of any system 
employed in an OA outcomes trial should be 
determined by a study group before the system is 
implemented. Management ofarthroscopic data by 
videotaping each procedure provides an im- 
mutable record that can be reviewed by a blinded 
evaluator. However, video records do not convey 
certain impressions obtained in real time,:~such as 
three-dimensional perception and tactile feedback 
from probing the cartilage. Regardless of the 
recording technique, a systematic uniform method 
of collecting arthroscopic data is essential, and 
should be specifically delineated in any protocol. 
Discussion of the technical aspects of the 
arthroscopic procedure is beyond the purview of 
this report. However, the size and type of 
instrument used and conditions under which the 
procedure is performed should be uniform for all 
investigators in any particular study. 
F.2.5. Molecular markers 
Molecular markers have not been validated as 
outcome measures in clinical trials of OA 
(Appendix V). However, molecular markers have 
the potential of offering a unique way of assessing 
drug effects on specific disease mechanisms, and 
modes of action of drugs in phase I clinical trials 
[57-59]. The field is developing rapidly. For these 
reasons, trials should include collections of body 
fluid samples. Standardization of methods for 
collection and storage is important. 
G. S ta t i s t i ca l  methods  
There are specific statistical tasks in the design, 
implementation and analysis components of a 
clinical trial. General textbooks cover a broad 
range of topics regarding statistics in clinical trial 
research [60, 61]. 
G.1. DESIGN 
The predominant activity of the statistician is 
working with the researcher in developing the 
protocol. The protocol must clearly list the 
primary and secondary study objectives. Where 
appropriate, these objectives hould be rephrased 
as null versus alternative hypothesis to be tested. 
All protocols should specify the outcome 
measure(s) to be used for evaluating the study 
treatments and should contain sample size calcu- 
lations for all primary outcomes, indicating the 
required number of patients to achieve prestated 
power and significance levels, or a calculation of 
the power provided with a prestated sample size. 
Sample size calculations are based on the choice of 
experimental design (e.g. parallel groups, factorial 
design, more than one treatment group vs control) 
and require that explicit assumptions be made 
regarding the variance(s) in outcomes among study 
subjects and the desired _magnitude of change(s) in 
the outcome variable(s) during the study period; 
these assumptions should be stated explicitly in 
the protocol. Phase 3 studies should require a 5% 
or lesser level of significance and 80% or greater 
power to detect a protocol defined minimal 
clinically meaningful difference in the expected 
outcome between the treatment and control 
groups. These assumptions should, when possible, 
be based on available clinical/epidemiological 
data. 
Randomization is a method for assigning 
patients to a test or control treatment that is free 
of selection bias. The method for randomization 
should be specified in the protocol. Two general 
designs exist for randomization of patients to 
treatments: fixed randomization and adaptive 
randomization. Fixed randomization schemes may 
be completely random or may be constrained so as 
to ensure balance in the number allocated to 
various treatment groups (randomization i  blocks 
of fixed size, stratified random sampling). Ran- 
domization in blocks should be considered if 
patient enrollment is likely to continue over an 
extended period of time, or if the study population 
can be expected to change over the course of 
treatment. Stratification should be considered 
when patients are recruited from many sites. 
Adaptive randomization schemes hould be con- 
sidered when investigators equire that balance be 
achieved on multiple factors. 
G.2. IMPLEMENTATION 
Statistical quality control procedures are essen- 
tial to ensure the validity of the data collection 
and computer entry methods. Key data variables 
should be run through checking programs to 
ensure, at a minimum, that the data are within the 
permissible range of possible values, that missing 
data are flagged, that patients meet inclusion and 
exclusion criteria, and that patients' data forms 
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are obtained in a timely fashion, as per protocol. 
Double entry of all keyed data is preferred. A 
random sample of  data coded on data entry forms 
should be checked against original sources (e.g. 
forms from laboratories and/or the medical 
record). 
Once study eligibility is validated, subjects are 
enrolled (and possibly stratified on baseline 
factors), assigned a study identification and 
thereby randomized to treatment following the 
predetermined randomization plan. 
G.3. ANALYSIS 
Generally, comparisons among treatment groups 
should be made as an 'intent-to-treat' nalysis; that 
is, (1) patients hould be counted in the treatment 
group to which they were randomly assigned, (2) 
the denominator for a treatment should be all 
patients assigned to that treatment, and (3) all 
events (whether believed to be related to the 
disease process under treatment or not) should be 
counted in the comparison(s) of primary interest. 
An intent-to-treat analysis can lead to an 
underestimate of the true treatment effect, es- 
pecially if compliance is low, there are many 
treatment crossovers, or the denominator includes 
many patients who could not be followed for the 
outcome of interest. Secondary analyses might 
then be carried out on completers (those staying on 
the program to study end), controlling for 
compliance levels. In general, analyses focused on 
an individual patient's longitudinal response, 
using composite (multidimensional) outcomes, 
should be encouraged. The outcome dimensions 
could include symptoms and/or structural 
measurements. 
Some analytic methods used to compare treat- 
ments in trials are as follows: 
G.3.1. Comparison of proportions 
This method is valid provided that patients are 
subject o the same length of follow-up and the loss 
of follow-up is low, and occurs for the same 
reasons, across treatment groups. Statistical 
evaluation of the difference in proportions can 
be performed using Fisher's exact tests or chi- 
square test for larger samples. Examples include 
proportion who are 'pain free' and proportions 
experiencing serious adverse medical events. An 
example with respect o structure modifying drugs 
might include proportions developing joint space 
narrowing. 
G.3.2. Lifetable analysis 
This approach provides a means for dealing with 
varying duration of follow-up to achieve the 
primary endpoint and for dealing with cases where 
the primary endpoint does not occur by the end of 
the study ('censored ata'). Statistical comparisons 
of lifetable rates are often performed using a 'log 
rank' test. Examples include: time until  pain 
resolves, time until normalization of a laboratory 
parameter. 
G.3.3. Comparison of means 
This method is valid, subject to the same 
conditions required for comparing proportions (see 
above). Statistical evaluation of the difference in 
means can be performed using a two-sample t-test 
or the standard normal distribution for larger 
samples. Example: comparing average change in 
pain over the study period. 
G.3.4. Descriptive methods 
These are useful for assessing the baseline 
comparability of the treatment groups, and for 
secondary analyses assessing compliance issues. 
Descriptive statistics often include means, stan- 
dard deviations, and percents of subjects in 
different strata (e.g. gender). 
G.4. ADJUSTMENT PROCEDURES 
To be valid, evaluation of treatment effects must 
be performed on treatment groups that are 
comparable with respect o their baseline charac- 
teristics. Statistical adjustment for one or more 
sources of variation is often performed by using 
regression models. Multiple linear regression 
models are used for quantitative outcomes, 
multiple logistic regression models are used for 
binary outcomes, and Cox proportional hazards 
models are used to adjust rates calculated from 
lifetables. These methods are especially useful if 
the randomization scheme failed or if randomiz- 
ation was not used in allocating patients to 
treatment groups. 
G.5. INTERIM ANALYS IS  
The concept of interim analysis is that patients 
assigned to the inferior treatment should be 
removed from it as soon as the choice is clear. 
These methods provide statistically valid P-values 
by accounting for the multiple looks of the 
outcome data during the study period. The scheme 
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for interim analyses should suit the particular 
trial. The procedure of O'Brien and Fleming is one 
statistically valid method for adjusting the 
P-value. 
G.6. REPEATED MEASURES ANALYSES 
These methods are useful for quantifying the 
trend and tempo of outcomes repeatedly assessed 
during the course of a trial and during the 
extended follow-up period. Statistical evaluation 
of the difference in summary statistics (e.g. trend, 
or slope) can be performed using the analysis of 
variance for repeated measures. Comparisons 
across treatment groups are valid provided that 
patients are followed for the same length of time 
and there is no differential loss to follow-up. 
H. Summary  
H.1. SYMPTOM MODIFYING DRUGS 
The primary outcome variable is a specific 
aspect of joint pain, although a 'signal' symptom or 
some measure of function may also be studied. 
Trials of drugs with a rapid onset of effect can be 
as short as 1-4 weeks but may be as long as 12 
weeks. Longer trials (up to 2 years) may be needed 
to evaluate longer-term toxicity, determine opti- 
mal long-term dosing regimens, or establish 
long-term benefit. Supplemental escape analgesia 
should be minimized, monitored and discontinued 
prior to evaluation of efficacy. 
Some agents that provide symptom relief may 
not provide benefit until weeks after initiation of 
therapy. Under these circumstances, trials will 
vary from 3-12 months in length. If the agent is 
administered in courses, episodic readministration 
of the drug may be needed in long-term trials. 
Longer trials (up to 2 years) may be required to 
exclude toxicity or establish long-term benefit. 
H.2. STRUCTURE MODIFYING DRUGS 
These drugs are intended to prevent, retard, 
stabilize or reverse development of the morpho- 
logic changes of OA. Although this has been called 
'chondroprotection', the term is misleading and 
should be avoided, because all structures of the 
joint are involved in OA, not articular cartilage 
alone. The benefits of disease modifying therapy 
may not be apparent until years after the onset of 
treatment. The selection of high-risk groups may 
shorten the time of investigation. Improvement in
symptoms (i.e., joint pain) is not a requisite for the 
efficacy of a drug in this category. In these studies, 
it may be necessary to permit concomitant use of 
drugs for relief of symptoms (NSAIDs, analgesics). 
The confounding effects of glucocorticoids and 
NSAIDs in these trials is not yet understood and 
very restricted use of IA depocorticosteroids is 
recommended. 
Demonstration of structure modification will 
require the use of direct measures of joint anatomy, 
such as radiography, particularly measurement of 
the radiographic joint space. As stated above, the 
plain radiograph is presently the most repro- 
ducible and readily available method for assess- 
ment of disease modification. Studies are needed to 
validate surrogate markers of disease activity, 
since they may help shorten Phase 2 structure 
modifying drug trials. As an alternative to 
radiography, some trials may utilize arthroscopy. 
As we approach the beginning of the twenty-first 
century, concepts of clinical trials of OA drugs are 
changing. Methodology and techniques for the 
evaluation of new agents for OA have been refined 
dramatically over the last decade. We look forward 
to the future with excitement as we anticipate the 
development of new agents that may alter the 
symptoms and course of OA. The above recommen- 
dations are intended to help us ascertain which of 
these new agents are effective. 
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Append ix  II 
Cl inical assessment  techn iques  
N icho las  Be l lamy 
Core set  measures  
The core set of outcome measures for OA clinical 
trials developed at OMERACT III, contain three 
clinical measures: pain, physical function and 
patient global assessment with imaging for studies 
of 1 year or longer [1]. 
PAIN 
Pain is usua]ly measured on a rating scale 
(Likert or VAS) which grades perceived pain 
severity in one or severa] situations (e.g., noctur- 
nal, stair climbing, walking, rest, global) [2]. The 
pain subscale of the WOMAC OA Index has been 
va]idated for use in patients with hip and/or knee 
OA [3-6]. WOMAC is available in both Likert and 
10 cm VA scaled formats and in a ]arge number of 
alternate language translations. Although not 
recommended for use as a distinct pain scale, the 
AFI have been validated for use in hip and knee 
studies where the goal is to provide a weighted 
clinical severity score in which scores for 
pain/discomfort, stiffness, maximum distance 
walked and activities of daily living are summated 
into a single value [7, 8]. A similar approach can be 
used with the WOMAC in situations where a 
composite score (based on pain, stiffness and 
physical function) is required, using weights 
derived from the Patient Assessment of the 
Relative Importance of Symptoms (PARIS) Sec- 
togram [6]. The Health Assessment Questionnaire 
(HAQ) [9] pain scale or the AIMS [10] or AIMS2 
[11] may be of limited value for studies focusing on 
a single joint, because they are appropriated for 
studies measuring pain severity in both the upper 
and lower extremities. Options for OA hand studies 
are limited but ear]y experience with the pain 
subscale of an instrument termed the Australian/ 
Canadian (AUSCAN) Osteoarthritis Hand Index 
has been favorab]e [12]. 
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PHYSICAL FUNCTION 
Physical function/disability is usually measured 
on a rating scale (Likert, VAS) which grades the 
perceived severity or degree of disability in one or 
more activities of daily living (e.g., stair climbing, 
walking, etc) [13]. The physical function subscale 
of the WOMAC index has been validated for use in 
patients with hip and/or knee OA [3]. The index is 
available in both Likert and 10 cm VAS scaled 
formats and in a large number of alternate 
language translations. Although not recommended 
as a distinct physical function scale, the AFI 
have been validated for use in hip and knee 
studies, where the goal is to provide a weighted 
clinical severity score in which :scores for 
pain/discomfort, stiffness, maximum distance 
walked and activities of daily living are summated 
into a single score [7, 8]. A similar approach can be 
used with the WOMAC by weighting and aggregat- 
ing the pain, stiffness and physical function 
subscales using PARIS Sectogram weights [6]. An 
AFI developed by Dreiser and colleagues contains 
10 questions directed at functional disability in the 
hand [14]. Early experience with the function 
subscale of the AUSCAN Osteoarthritis Hand 
Index has been favorable [12]. In studies measuring 
physical disability in both the upper and lower 
extremities, the physical function subscale of the 
HAQ [9] or AIMS [10] (or AIMS2) [11] instruments 
is appropriate. 
PAT IENT GLOBAL ASSESSMENT 
The patient's perception of the clinical severity 
of their OA is usually assessed by a direct question, 
e.g., 'Considering all the ways your OA affects you, 
how would you rate your condition today?' 
Suitable response scales could include the follow- 
ing: Likert--very poor, poor, fair, good, very good; 
or 10 cm horizontal VAS anchored to very poor 
(left hand end) and very good (right hand end). 
Alternatively, or in addition, at the end of the 
study a change in score could be derived using a 
similar question, e.g., 'Considering all the ways 
your OA has affected you, how do you feel now 
compared with the beginning of the study?' 
Responses could be made on a Likert scale, e.g., 
'much better', 'better', 'no change', 'worse', 'much 
worse'. There is currently no standard question 
and no standard response format [15]. It should be 
noted that depending on the research ypothesis, 
there are several ways of phrasing the global 
question, e.g., musculoskeletal condition, OA in 
the study knee, overall health, etc. Investigators 
should be guided by questions and response 
formats that have been used successfully in past 
studies or should develop and validate new 
standardized questions. 
Non-core  set  measures  
HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND 
UTILITY (UT)  MEASURES 
HRQOL and/or UT measures are increasingly 
being considered as very important components of 
the measurement battery for studies of 6 months or 
longer. They not only allow measurement of the 
patient's quality of life or the util ity of their health 
state, but also facilitate pharmacoeconomic and 
cross-disease comparisons of outcome. There is 
relatively little experience to date with these 
instruments (e.g., SF-36 [16], EuroQol [17], Notting- 
ham Health Profile [18], Health Utilities Index [19], 
Standard Gamble [20], Time Trade Off [21], 
Category Scaling [22]) in OA trials. However, 
because of their potential importance, use of 
HRQOL and/or UT 'measures is highly rec- 
ommended in Phase 3. trials of 6 months or 
longer. It is expected that there will be improve- 
ment in our knowledge of the performance of one 
or more of these instruments, their role in Phase 3 
clinical trials and the relative impact that 
interventions have on different measures will 
evolve over the next few years. Comparing 
different measures in the same trial would be 
particularly useful. 
PHYSICIAN GLOBAL ASSESSMENT 
The physician's perception of his or her patient's 
OA can be based on a number of different 
variables, e.g., symptoms, signs, imaging, and, 
possibly, in the future, biologic markers. It is 
important to specify in the question or in 
accompanying instructions which variables hould 
be considered in making the assessment. Usually, 
this will be based on symptoms, and since the 
clinical encounter will likely be quite brief, the 
question should be phrased with respect o the day 
of assessment, e.g., 'Considering all the ways OA 
affects your patient, how would you rate his or her 
condition today?' Suitable response scales could 
include the following: Likert--very poor, poor, 
fair, good, very good; or 10 cm horizontal VAS 
anchored to very poor (left hand  end) and very 
good (right hand end). Alternatively, or, in 
addition, at end of study a change score can be 
derived using a similar question, e.g., 'Considering 
all the ways OA has affected your patient, how do 
you rate their condition now compared with the 
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beginning of the study?' Responses could be made 
on a Likert scale, e.g., much better, better, no 
change, worse, much. There is currently no 
standard question and no standard response 
format [15]. Investigators hould be guided by 
questions and response formats that have been 
used successfully in past studies or should develop 
and validate new standardized questions. It should 
be noted that depending on the research ypoth- 
esis, there are several ways of phrasing the global 
question, e.g., musculoskeletal condition, OA in 
study knee, overall health, etc. 
PERFORMANCE-BASED MEASURES 
Many performance based measures are avail- 
able, some of which are of demonstrated reliability, 
validity and responsiveness [15,23]. Although 
providing numerical estimates of performance, the 
clinical consequence to individual patients of any 
change for the better or worse on such measures 
lacks clarity. As a consequence, while sometimes 
useful in certain types of studies, they are not 
included in the core set. Measures that have been 
employed include: walking distance, walk time, 
grip strength [23]. It is important with these 
measures ~o use standard techniques and to train 
assessors to acceptable levels of inter-observer 
reliability [15]. 
EXAMINATION BASED MEASURES 
The clinical examination provides an opportu- 
nity to detect swelling (bony, soft tissue, effusion), 
crepitus, heat, range of movement, deformity, 
l igamentous laxity, range of movement (goniome- 
ter, plurimeter, intermalleotar straddle, inter- 
condylar  distance, heel to buttock test) [15, 23]. 
These assessmentsrequ i re  standard methods 
applied by trained assessors [15]. In general, as 
with performance-based measures, changes for the 
better or worse occurring on these examination- 
based measures lack defined levels of clinical 
importance to individual patients. They may be 
useful in some types of study but are not in the core 
set. 
MISCELLANEOUS 
'Stiffness' is a sense of resistance or decreased 
ease during active movement of the joint. Some, 
but not all, patients have difficulty differentiating 
between pain and stiffness. When stiffness is 
measured in clinical trials, it is preferable to use 
the WOMAC [3-6] or AFI [7, 8] (depending on 
whether a segregated or aggregated stiffness core 
is required) for hip and knee studies. The 
assessment of stiffness may be useful in some types 
of studies but has not been validated as an outcome 
in OA and is not in the core set. 
' Inflammation' has not been extensively studied 
in OA clinical trials. As a result, the validity, 
reliabil ity and responsiveness of inflammatory- 
based measures remain in doubt. They may be 
useful in some types of study but are not val idated 
in OA and are not in the core set. 
'Number of "F lares" '  and the occurrence of 
disease 'flares' in OA lacks precise definition and 
as a result is difficult to reliably identify. This 
variable has not been included in the core set. 
'Time to surgery' is influenced by a large number 
of factors, independent of the study intervention, 
e.g., the dynamics of scheduling operating time. 
Although this variable may be useful in some 
studies it has not been validated as an outcome in 
OA and is not included in the core set. 
'Analgesic consumption' is an important source 
of cointervention; however, the precision with 
which analgesic consumption can be monitored, 
part icularly in long-term studies, is suboptimal. 
RESPONSE CRITERIA  
Response criteria may apply to groups of 
patients or individuals. The definition of a 
minimum clinically important difference between 
two groups of patients exposed to different 
interventions, depends on a number of factors 
relating to patient characteristics, disease fea- 
tures, the nature of the interventions, and the 
primary outcome measure selected. It is difficult to 
determine stimates of minimum clinically import- 
ant differences for OA clinical studies [15]. At the 
present time there are no standard criteria for 
defining the success, or failure, of t reatment in 
individual OA patients in a clinical trial. 
Summary  
The core set of outcome measures for OA clinical 
~.trials requires measurement of pain, physical 
function, patient global assessment, and imaging 
procedures for studies of 1 year or longer. 
Depending on the research hypothesis, one of 
several existing validated measures can be selected 
for evaluating change in each of the four domains. 
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Appendix III 
Radiographic imaging techniques 
J. Christopher Buckland-Wright, 
William W. Scott Jr, Charles Peterfy 
The reproduc ib i l i ty  of the rad iograph ic  techn ique 
is dependent  on contro l  of  a number  of techn ica l  
issues. The discussion below presents  a few 
methods that  a t tempt  to s tandard ize  many of the 
re levant  techniques.  Other  methodolog ies  exist. 
Such s tandard izat ion  is essent ia l  in order  to 
re l iab ly  assess sequent ia l  changes  in jo int  anat-  
omy. The most  cons is tent  results  will be obta ined  
by carefu l ly  adher ing  to s tandard ized rad iograph ic  
procedures,  based on publ ished, va l idated data.  
Qual i ty  contro l  of  personne l  and procedures  is 
essent ia l  for mul t i center  or comparat ive  studies. 
The methods  descr ibed below require no special  
faci l i t ies other  than  f luoroscopy. 
Hip joint 
PAT IENT POSIT ION 
Anteroposter io r  rad iographs  are obta ined wi th  
the pat ient  standing.  Weight  bear ing  compresses  
the jo int  space to its most  nar row conf igurat ion 
[1, 2]. The feet are pos i t ioned in in terna l  ro ta t ion  
with the toes subtend ing  an angle  of 15 _+ 5 ° [3]. A 
foot map,  used to fac i l i tate repos i t ion ing at  
successive visits may improve measurement  repro-  
ducibi l i ty.  However ,  a foot map a lone does not  
assure ident ica l  repos i t ion ing as the body can 
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torque about the knee. Reproducibil ity requires 
multipoint control. 
X-RAY BEAM AL IGNMENT 
With a focus to film distance of 100 cm, the X-ray 
beam must be horizontal and perpendicular to the 
film. When the X-ray beam is centered on the 
superior aspect of the symphysis pubis to radio- 
graph both hips together. There is less accuracy 
and precision in the joint space width measure- 
ment than when the central ray of the X-ray beam 
is aligned with the center of each femoral head 
[3-5]. 
RADIOGRAPHIC  MAGNIF ICAT ION 
In view of the variable distance between hip 
joint and film among individuals, variable radio- 
graphic magnification can occur. A metal sphere of 
known size (10 mm), mounted in a semi-radiolucent 
material and taped to the skin over the greater 
trochanter can be used to correct for radiographic 
magnification at the joint. This is needed only if 
significant weight change has occurred between 
visits to alter this distance. An increase in the 
number of study patients may be needed without 
correction for radiographic magnification. 
Knee jo int:  t ib io - femora l  compar tment  
STANDING FULLY  EXTENDED V IEW [6-9] 
Patient position 
Separate anteroposterior radiographs of each 
knee are obtained with the patient standing and 
the weight equally distributed to both feet. The 
knee must be in full extension, with the back of the 
knee as near as possible to the vertical cassette. 
With the aid of fluoroscopy, the lower limb is 
rotated so that the tibiai spines appear centrally 
placed relative to the femoral notch, A foot map 
may be used to facilitate repositioning at succes- 
sive visits. 
X-ray beam alignment 
The central ray of the X-ray beam is centered on 
the joint space and inclined downward to ensure 
that the medial tibial plateau is parallel to the 
X-ray beam. 
Correction for radiographic magnification 
It is only necessary to correct for radiographic 
magnification if the distance between the back of 
the knee and the vertical cassette is altered in 
subsequent examinations ( ee above). 
STANDING PARTIALLY  FLEXED V IEW [3, 10, 11] 
Patient position 
Separate anteroposterior radiographs of each 
knee are obtained with the patient standing. Each 
knee is flexed until the tibial plateau is horizontal 
relative to the floor, and therefore parallel to the 
central X-ray beam which is oriented perpendicu- 
lar to the X-ray film. The degree of flexion varies 
among individuals due to differences in the angle 
of inclination of the tibial plateau. The precise 
inclination is obtained with the aid of fluoroscopy. 
With the heel fixed, the foot is internal ly or 
externally rotated until the tibial spines appear 
centrally placed relative to the femoral notch. A 
foot map may be used to facil itate joint reposition- 
ing at successive visits; patients are provided with 
hand supports to ensure their stability. 
X-ray beam alignment 
With a focus to film distance of 100 cm, the X-ray 
beam, must be horizontal to the floor, perpendicu- 
lar to the film, and aligned with the center of the 
joint. 
Radiographic magnification 
Correction for the effect of radiographic magnifi- 
cation includes a metal sphere of known size 
(5 mm) taped above the head of the fibula. The 
dimension of this ball is used to  determine the 
degree of radiographic magnification at the joint. 
This is only needed if there is variation in knee to 
film distance between visits. 
Published studies may guide the calculation of 
numbers needed for a structure modifying drug 
trial T12, 13]. 
Wrist  and hand jo ints  
PAT IENT POSIT ION 
Dorsopalmar radiographs of ~he wrist and hand 
are obtained with the fingers held together and in 
line with the axis of the wrist and forearm, since 
spreading the fingers may alter joint al ignment 
and lead to an incorrect assessment of joint space 
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loss. A hand map may be used to fac i l i tate precise 
repos i t ion ing at successive visitsl 
X-RAY BEAM AL IGNMENT 
The tube is pos i t ioned at  a focus to film d istance 
of 100 cm. The centra l  ray of the X-ray beam is 
centered vert ica l ly  at  the head of the th i rd  
metacarpa l  bone. 
Landmarks  for measurement  
JO INT  SPACE WIDTH OR INTERBONE DISTANCE 
J o in t  space nar rowing  corre lates  with cart i lage 
th ickness in OA [13]. Because cart i lage loss in OA 
is not  un i form across the jo int  [14], min imum jo int  
space width is the appropr ia te  measurement  [15]. 
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Append ix  IV 
Magnet ic  resonance  imag ing  
Char les Peter fy  
MRI is a re lat ive ly  new imaging technique,  but  its 
ut i l i ty for eva luat ing  s t ructura l  derangements  of 
d iar throd ia l  joints, such as menisca l  tears,  cruci- 
ate l igament  ruptures  and bone injur ies is a l ready  
wel l -establ ished in cl inical  pract ice.  Recent  tech- 
niques show promise for ser ia l  quant i f icat ion of 
the volume, th ickness,  geometry  and compos i t ion  
of a r t i cu la r  car t i lage [1]. These techniques are so 
new, however ,  that  only a few have been va l idated 
cross-sect ional ly  and none has been assessed 
longitudinal ly .  
Poss ib le  uses  of  MRI 
MRI  is un iquely  suited for mon i tor ing  s t ruc tura l  
changes in  OA, for it is capable  of d i rect ly  
examin ing all components  of the jo int  simul- 
taneously.  In addi t ion to del ineat ing anatomy,  
however,  MRI  shows promise for quant i f icat ion of 
compos i t iona l  and funct iona l  parameters  of art icu-  
lar tissues. 
MEASURING CARTILAGE MORPHOLOGY 
Fat-suppressed,  T l -we ighted three-d imens ional  
(3D) grad ient  echo imaging can del ineate ar t i cu la r  
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carti lage morphology in the knee [2-6]. and fingers 
[7,8]. In a recent study of 48 knees [4,5], this 
technique demonstrated a sensitivity of 86% and 
specificity of 97% for identifying carti lage defects 
which were visible on arthroscopy. The surface 
topography of individual carti lage plates as well as 
contact-areas between opposing art icular surfaces 
can be mapped [9]. Accurate measurement of 
carti lage thickness requires spatial resolution 
better than 10% of that  thickness (e.g., 200 ~m 
in-plane resolution for a 2-mm thick cartilage). 
This is possible with conventional MRI, but 
generally beyond what is performed uring routine 
clinical imaging. Considerably less resolution is 
required to quantify carti lage volume in the knee 
[3] or the metacarpophalangeal  [7]. Validation of 
the longitudinal reproducibi l i ty of carti lage vol- 
ume measurement and its sensitivity to volume 
changes will not be available for several years. 
MEASURING CARTILAGE QUALITY 
MRI may be able to probe the composition of 
art icular cartilage. Areas of matrix loss and 
increased water content in the carti lage may cause 
focal signal intensity alterations and it may be 
possible to map the fractional water content of 
normal and abnormal carti lage [10]. This tech- 
nique, however, must await further optimization 
and validation. Other parameters of art icular 
carti lage integrity, such as water diffusivity 
[11, 12], proteoglycan content [13, 14], collagen 
content and organization [15, 16] and compressive 
stiffness, may be measurable in the future. Should 
these advancements occur, MRI may replace 
radiography as the standard imaging method. 
EVALUATING OTHER ARTICULAR T ISSUES IN OA 
MRI also provides information about the 
severity of synovial inflammation, the integrity of 
IA l igaments and menisci, the status of periarticu- 
lar muscles andtendons,  the presence of subartic- 
ular bone marrow edema, and the morphology of 
the art icular bones (including the size, number and 
location of osteophytes and subchondral cysts) 
[17, 18]. 
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Append ix  V 
Methods  for co l lect ion and s torage of  body 
fluid samples  
Stefan Lohmander  
Most of the published studies on markers have 
focused on analyzing cartilage-derived products; 
however, markers of the metabolism of other joint 
tissues, such as meniscus, synovium and bone 
should also be considered. In addition, markers of 
genetic susceptibility, and cellular activity or 
other processes that might be relevant to the 
pathogenesis of OA should also be given consider- 
ation. The following represents an update and 
summary of the previously published guidelines for 
sample collection and storage [1]. 
Sample  co l lect ion 
Three biological fluids are potential sources for 
markers in OA studies: urine, blood and synovial 
fluid. Guidelines for collecting these samples 
should minimize manipulations at the site of 
collection. While this probably does not present 
difficulties with urine and blood, some special 
problems are noted below for synovial fluids. In 
general, samples hould be processed so that they 
may be frozen at the collection site in small 
screw-cap tubes designed for storage. Additional 
manipulations, involving dilution, aliquoting, 
storage and shipping of collected specimens to 
laboratories performing the marker assays would 
be best accomplished by a referral center with 
appropriate facilities and trained personnel. Due 
to the possibility of circadian variations in marker 
levels, care should be taken to collect samples at 
the same time of the day in longitudinal studies. 
URINE 
Specimens should be obtained as the second void 
in the morning; spot sampling would be acceptable; 
however, time of collection must be recorded. 
Specimens should be chilled to 4°C and clarified in 
a clinical centrifuge within 4 h. Approximately 
25 ml should be aliquoted into a 50 ml po!ypropy- 
lene tube with a screw cap. The specimen should 
be clearly labeled and stored frozen (see below). 
BLOOD 
Approximately 25 ml blood should be taken from 
the antecubital vein after fasting, and collected in 
either plain, heparin or EDTA tubes. The choice of 
tubes is dictated by the effect either may have on 
the marker assays eventually chosen. For example, 
some heparin samples may contain interfering 
substances in assays for carbohydrate epitopes on 
chondroitin sulfate or keratan sulfate. The samples 
should be kept at 4°C until plasma (or serum) can 
be prepared by centrifugation in a clinical 
centrifuge, preferably Within 4h. The clarified 
plasma (or serum), should be aliquoted into 
'Eppendorf-type' tubes (1 mt per tube). The tubes 
should be clearly labeled and stored frozen (see 
below). Although the collection of serum may be 
simpler, it was argued that plasma samples could 
be preferred for some marker assays, and may also 
be a source of DNA for analysis of genetic 
susceptibility. If analysis of genetic material is 
planned as a specific target, preparation and frozen 
storage of buffy coat is recommended. 
SYNOVIAL  FLU ID 
Synovial fluid should, if at all possible, be 
collected undiluted, i.e. without lavage. In cases 
without joint swelling and exudate, synovial fluid 
volumes will be small. Up to 10 aliquots of 1 ml 
should be distributed into 1.5-2.0 ml 'Eppendorf- 
type' tubes. Any remaining larger volumes can be 
stored in larger size aliquots. The tubes should 
contain EDTA in appropriate amounts to prevent 
fibrin clot formation. The tubes should be suitable 
for centrifugation i  a higher speed centrifuge, 
such as a microfuge. The higher speeds are 
required to remove cells and debris from the 
samples which are frequently very viscous. 
Samples should be kept at 4°C and centrifuged 
within 4h. Clarified supernatants hould be 
transferred into appropriate sized (2 or 20ml) 
polypropylene tubes with screw caps. The 
specimens hould be clearly labeled and stored 
frozen, preferably at -70°C, prior to shipment to a 
referral center. A recommendation for sample 
centered information that should always be 
available, to complement the core clinical data, is 
included (Table I). 
Osteoarthritis and Cartilage Vol. 4 No. 4 243 
Table I. 
Sample centered ata to be collected with all specimens 
Urine 
First or subsequent a.m. void, or other time of 'spot' 
sample 
Serum 
Site of venepuncture 
(if not antecubital, vein, where) 
Synovial fluid 
Total volume withdrawn 
Lavage used (yes/n0)~if yes, volume 
For all 
Date and time sample was taken 
Have guidelines for handling and storage been 
adhered to 
(if no, provide details) 
At what temperature have samples been stored 
Referral  co l lect ion  centers  
The collection center  should have defined 
protocols for thawing, diluting, aliquoting, coding 
(consider bar coding), freezing and storing the 
specimens received. Accompanying clinical and 
chemical data, required by the clinical protocol 
and any accessory information, would be encoded 
into a data bank system. This center would also 
distribute appropriate sample sets to laboratories 
conducting the marker assays. Results of the 
assays would be sent to this center and entered 
into the data bank. For synovial fluid samples, 
volumes will often be small, and a minimum set of 
aliquots could be prepared based upon a lml  
volume. A measured volume, e.g. I ml, should be 
diluted with four volumes of physiological saline 
supplemented with either EDTA or heparin 
depending upon the original choice. Aliquots of 
250pl should then be distributed into small 
volume, coded polypropylene tubes with O-rings 
and screw caps. This dilution and sampling 
protocol will yield around 20 identical samples for 
each original synovial fluid sample. For synovial 
fluid samples with larger volumes, we recommend 
preparing at least one such set of 20 identical 
standards, and then storing the remainder of the 
1:4 diluted samples in larger aliquots (5 or 10 ml) in 
appropriate tubes for long-term storage. All 
storage should be at -70°C. 
Freez ing  and sh ipp ing 
Freezing and thawing of samples should be 
minimized, as some markers may loose antigenicity 
in the process. Storage at -70°C is preferable if 
such freezer capabilities are available at the site of 
sample collection. In this case, the samples can be 
stored for long periods of time. If this option is not 
available, samples can be stored at -20°C in a 
freezer which does not have an automatic defrost 
cycle. Samples collected uring a week should then 
be sent on dry ice to a referral collection center. 
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